AIROS Medical

AIROS Medical

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15.2M

Overview

AIROS Medical is a private, commercial-stage medical device company focused on the large and growing market for compression therapy. Founded by Durable Medical Equipment (DME) industry veterans, the company leverages deep clinical and reimbursement expertise to develop and commercialize pneumatic compression pumps and garments. Its core AIROS 6 and AIROS 8 systems treat lymphatic and venous conditions, with a recent strategic expansion into the arterial disease segment via the FDA-cleared ARTAIRA device. The company appears to be in a revenue-generating phase, selling through DME suppliers and directly to patients/therapists.

LymphedemaChronic Venous InsufficiencyLipedemaPeripheral Arterial Disease

Technology Platform

Pneumatic compression therapy platform featuring programmable, multi-chamber sequential gradient pumps (including peristaltic modes) and a suite of specialized garments for lymphatic/venous drainage and, separately, high-pressure intermittent compression for arterial blood flow augmentation.

Funding History

2
Total raised:$15.2M
Series A$12M
Seed$3.2M

Opportunities

The launch of ARTAIRA opens the large and growing Peripheral Arterial Disease (PAD) market, providing a significant new growth vector beyond the core lymphedema business.
The chronic nature of all target conditions ensures recurring revenue from garment replacements and creates a stable, long-term patient base.

Risk Factors

The business is heavily dependent on insurance reimbursement, which is subject to policy changes and can be complex to navigate.
The company faces intense competition in the compression therapy market from both large established players and smaller innovators, requiring continuous differentiation.

Competitive Landscape

AIROS competes in the pneumatic compression therapy market against companies like Tactile Medical (lymphedema pumps), Bio Compression Systems, and Lympha Press. Its expansion into PAD with ARTAIRA places it against other arterial assist devices and broader PAD treatment modalities, including pharmaceuticals and surgical interventions.